Carsten E. Palme

Chris O’Brien Lifehouse — Australia

Medicine · Health Sciences

37h-index5.5kcitations265works1.12yr avg

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Head and Neck Cancer Studies(72), Nonmelanoma Skin Cancer Studies(52), Ear and Head Tumors(46), Salivary Gland Tumors Diagnosis and Treatment(38), Tracheal and airway disorders(29)

Publications264 total

Economic evaluation of microvascular reconstruction of the jaw: A micro-costing analysis and identification of key cost-drivers

Oral Oncology·2026

A comparison of health-related quality of life using Jaw-in-a-Day surgery versus jaw reconstruction with primary endosteal implant placement and secondary prosthetic rehabilitation

1 cited

Journal of Plastic Reconstructive & Aesthetic Surgery·2026· 1 cited

Prognostic Factors Affecting Survival in Patients With Head and Neck Adenoid Cystic Carcinoma: A Single-Institution Experience

Cureus·2025Open Access

Circulating tumor cells predict relapse in head and neck mucosal squamous cell carcinoma

European Journal of Surgical Oncology·2025Open Access

Supplementary Table S11 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in TFCP2 Fusion–Defined Rhabdomyosarcoma

2025Open Access

Data from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in TFCP2 Fusion–Defined Rhabdomyosarcoma

2025Open Access

Supplementary Fig. S1 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in TFCP2 Fusion–Defined Rhabdomyosarcoma

2025Open Access

Supplementary Fig. S4 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in TFCP2 Fusion–Defined Rhabdomyosarcoma

2025Open Access

Supplementary Table S10 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in TFCP2 Fusion–Defined Rhabdomyosarcoma

2025Open Access

Supplementary Table S4 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in TFCP2 Fusion–Defined Rhabdomyosarcoma

2025Open Access

Supplementary Table S9 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in TFCP2 Fusion–Defined Rhabdomyosarcoma

2025Open Access

Supplementary Table S1 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in TFCP2 Fusion–Defined Rhabdomyosarcoma

2025Open Access

Supplementary Fig. S3 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in TFCP2 Fusion–Defined Rhabdomyosarcoma

2025Open Access

Supplementary Fig. S5 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in TFCP2 Fusion–Defined Rhabdomyosarcoma

2025Open Access

Supplementary Fig. S6 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in TFCP2 Fusion–Defined Rhabdomyosarcoma

2025Open Access

Supplementary Fig. S2 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in TFCP2 Fusion–Defined Rhabdomyosarcoma

2025Open Access

Supplementary Table S3 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in TFCP2 Fusion–Defined Rhabdomyosarcoma

2025Open Access

Supplementary Table S8 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in TFCP2 Fusion–Defined Rhabdomyosarcoma

2025Open Access

Supplementary Table S2 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in TFCP2 Fusion–Defined Rhabdomyosarcoma

2025Open Access

Supplementary Table S7 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in TFCP2 Fusion–Defined Rhabdomyosarcoma

2025Open Access

page 1 of 14Next →

Frequent Co-authors

Jonathan R. Clark(20), Michael Veness(15), Gary J. Morgan(15), Ruta Gupta(14), Sydney Ch’ng(11), Tsu‐Hui Low(10), Bruce Ashford(9), Ardalan Ebrahimi(8), Kan Gao(7), Faruque Riffat(5), Val Gebski(4), Matthew Campbell(4), Kerwin F. Shannon(4), Patrick Gullane(4), Jeremy L. Freeman(4), Peter R. Eastwood(3), Maree Barnes(3), Jennifer H. Walsh(3), Kathleen J. Maddison(3), John R. Wheatley(3)